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ABSTRACT
eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent 
translation. This study is the first to demonstrate that 4E-BP1 expression correlates 
with colorectal cancer (CRC) progression. Compared to its expression in normal colon 
epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient 
tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with 
poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. 
Our previous data showed that YXM110, a cryptopleurine derivative, exhibited 
anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could 
inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by 
YXM110 under hypoxic conditions, implying that cap-independent translation could be 
suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1α (HIF-
1α) expression, which resulted in decreased downstream vascular endothelial growth 
factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker 
and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer and the third leading cause of cancer related deaths 
worldwide [1]. Approximately 50–60% of diagnosed CRC 
patients will develop metastases. Most cases of CRC are 
sporadic, with only a small proportion related to heredity. 
It has been reported that some gene mutations increase the 
incidence of CRC, including those of APC (adenomatous 
polyposis coli), KRAS, MLH1, MSH2, TP53, and EGFR 
[2]. Currently, the cornerstone treatment for CRC is 
surgery for stage I cases, with adjuvant radiotherapy and 
systemic chemotherapy for stages II and III. In addition to 
traditional chemotherapy drugs (5-fluorouracil, irinotecan, 
and oxaliplatin), several targeted monoclonal antibodies 
such as bevacizumab, cetuximab, panitumumab, and 
capecitabine have been utilized in the clinic [3].
There has been an increased focus in the past few 
years on individualized therapy for cancer treatment. 
Traditional systemic chemotherapy often results in off-
target toxicity in patients with a resulting loss in quality 
of life. Therefore, the development of prognostic and 
predictive markers would be advantageous for the 
development of targeted therapeutics. Recently, several 
valuable molecular markers have been discovered for 
CRC. Microsatellite instability (MSI), a kind of genome 
instability, results from a dysfunction in mismatch repair 
genes and often occurs in cancers. An evaluation of the 
Oncotarget24093www.impactjournals.com/oncotarget
effect of high MSI on patient survival in 5-FU treated 
and untreated CRC patients demonstrated that untreated 
patients with high MSI had improved overall survival 
compared to high MSI patients treated with 5-FU [4]. MSI, 
18q loss of heterozygosity, p53, SMAD4, thymidylate 
synthase, KRAS, and BRAF genes have been shown 
to be important indicators of CRC pathogenesis. Other 
markers, such as the tumor suppressor, guanylyl cyclase 
2 and the nucleotide excision repair gene, ERCC1 are 
also being considered as possible predictive markers [5], 
which emphasizes the importance of identifying relevant 
biomarkers for the design of targeted drugs.
Protein synthesis controls cell growth, cell size 
maintenance, proliferation, and the survival of cancer cells 
[6]. Translation phases include the rate-limiting step of 
initiation, the assembly of the elongation-competent 80S 
ribosome, and termination. Translation of mRNAs can 
occur in a cap-dependent and cap-independent manner. Cap-
tagged mRNAs recruit eukaryotic initiation factors (eIFs), 
forming the eIF4F complex, composed of the following 
proteins: scaffolding protein eIF4G, RNA helicase eIF4A, 
and the cap-binding protein eIF4E [7]. eIFs work together to 
initiate the translation process. However, recent studies have 
indicated that cap-independent translation may contribute to 
cancer progression. Unlike cap-dependent translation, cap-
independent translation involves access to mRNAs through 
an internal ribosome entry site (IRES) without cap binding. 
Under cellular stress such as in hypoxia, cap-independent 
mRNAs can be translated even when cap-dependent 
translation is decreased [8]. Cellular mRNAs that also 
contain IRES elements include hypoxia-inducible factor 
1α (HIF1A), vascular endothelial growth factor (VEGFA), 
fibroblast growth factor 2 (FGF2), and BCL2, all of which 
utilize a dual mechanism of initiation (cap or IRES) [9, 10].
4E-BP1, the most common eukaryotic translation 
initiation factor of 4E binding proteins (4E-BPs) impacts 
cell proliferation, apoptosis, invasion, and metastasis. The 
hypophosphorylated active form of 4E-BP1, sequesters 
eIF4E and prevents it from binding to eIF4G, thus blocking 
the formation of the cap-dependent translation complex 
(eIF4F). 4E-BP1 also activates cap-independent translation 
by binding to eIF4E [11]. It has been shown that elevated 
levels of 4E-BP1 and eIF4G induces hypoxia mediated 
inhibition of cap-dependent mRNA translation and increases 
the translation of mRNAs containing IRES. This leads to 
angiogenesis, hypoxia resistance, and survival [6, 8]. Cap-
independent translation is also highly correlated with drug 
resistance under hypoxic conditions [12].
Oxygen is necessary for cells to produce adequate 
amounts of ATP to support cellular metabolic activities. 
Hypoxic conditions are often observed within cancer tissues, 
due to the high proliferation rates and vascular abnormalities 
[13]. Hypoxia-inducible factor-1 (HIF-1), an oxygen-
sensitive transcription factor, initiates adaptive responses to 
changes in oxygen tension in various microenvironments 
[14]. HIF-1 is a heterodimer protein complex composed 
of a constitutively expressed HIF-1β subunit and a highly 
regulated HIF-1α subunit [15]. The balance between protein 
synthesis and protein degradation determines the expression 
level of HIF-1α. During hypoxia, the protein synthesis 
process for HIF-1α mRNA switches from cap-dependent 
to cap-independent (IRES-dependent) translation [6]. 
Accumulated HIF-1α dimerizes with HIF-1β and binds to 
hypoxia-response elements (HREs) within the promoters of 
target genes, such as VEGF, glucose transporter 1 (GLUT1), 
erythropoietin (EPO), and nitric oxide synthase (NOS) 
[16]. HIF-1α overexpression and activation stimulates 
several key pathways in carcinogenesis, such as those 
related to angiogenesis, anaerobic glucose metabolism, 
dedifferentiation, and invasion [13].
The phenanthroquinolizidine alkaloid cryptopleurine, 
is a natural product isolated from the Asclepiadaceae and 
Moraceae families. Its anticancer activity in drug-resistant 
cancer cells has been elucidated [17–19]. YXM110 was 
shown to be the most potent cryptopleurine derivative against 
seven cancer cell lines. We previously reported that YXM110 
inhibited global protein synthesis, and stimulated the 
degradation of 4E-BP1 and regulation of autophagy, which 
ultimately led to tumor suppression [20]. YXM110 induced 
decrease in 4E-BP1 expression in an in vivo xenograft model 
further confirmed its antitumor effect (unpublished data). 
We previously also found that under hypoxic conditions, 
YXM110 had the ability to reduce 4E-BP1 protein levels 
and compared to paclitaxel, cells showed less resistance to 
YXM110. Consequently, we suggested that 4E-BP1 depletion 
could be a benefit for an anticancer drug development.
To our knowledge, this study is the first to 
demonstrate that the expression of 4E-BP1 correlates with 
patient survival time and recurrence in CRC. Significantly 
increased 4E-BP1 levels were observed in all colon cancer 
cell lines tested as well as in the cancer tissues of patients. 
Clinical pathology analysis demonstrated that 4E-BP1 
expression is associated with poor prognosis and cancer 
stage. Under hypoxia, 4E-BP1 is thought to be an important 
factor for cap-independent translation. Our previous 
study showed that YXM110 significantly suppressed 
the expression of 4E-BP1 [20]. Therefore, in the present 
study, we investigated whether YXM110 could inhibit 
protein synthesis under hypoxic conditions. We found that 
YXM110 markedly decreased 4E-BP1 expression, resulting 
in diminished HIF-1α-regulated VEGF expression. Taken 
together, our findings indicate that 4E-BP1 could be a 
valuable prognostic biomarker, and YXM110 appears to be 
a promising lead compound for CRC therapy.
RESULTS
4E-BP1 is upregulated in CRC cell lines and 
tumor tissues
To elucidate the mechanistic link between 4E-BP1 
and CRC, we assessed the basal levels of 4E-BP1 in 6 colon 
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cancer cell lines (SW480, SW620, Colo205, Caco-2, HCT116, 
and HT-29) and 1 normal colon cell line, CCD-18co, under 
normoxia and hypoxia. The lowest basal protein expression 
levels of 4E-BP1 were observed in normal CCD-18co colon 
cells compared to colon cancer cell lines, under normoxic 
and hypoxic conditions (Figure 1A, 1B and Supplementary 
Figure S1A). In addition, the expression of 4E-BP1 was 
dramatically increased under hypoxic conditions, especially 
in the CRC cells, compared to its expression under normoxic 
conditions. This indicates that 4E-BP1 might mediate hypoxia-
induced drug resistance (Figure 1C). Notably, the expression 
levels of 4E-BP1 in SW480, SW620, and Colo205 cells, 
derived from Duke’s B-, C-, and D-type CRC, respectively, 
appeared to be elevated depending on disease progression. 
Caco-2 is a well-differentiated colon cancer cell line. However, 
4E-BP1 levels in these cells were only slightly higher than in 
normal CCD-18co cells.
4E-BP1 expression in CRC tissues was also 
evaluated, and 4E-BP1 was more highly expressed in 
cancerous colon and rectal tissue sections than in the 
corresponding non-cancerous sections (Figure 2A, 2B). 
The liver is the predominant metastatic site for CRC 
patients. Therefore, we also assessed 4E-BP1 expression 
levels in the liver in rectum metastases patients. Liver 
tissue from non-metastatic CRC patients expressed lower 
levels of 4E-BP1 than liver tissue from metastatic CRC 
patients. Taken together, the above results suggest that 
4E-BP1 expression and tumor progression are related.
Association of 4E-BP1 expression with  
clinical parameters
The association between 4E-BP1 and several clinical 
parameters, including sex, age, TNM, and cancer stage, was 
analyzed in 192 CRC patients (Table 1). Cancerous and 
non-cancerous tissues were sectioned into four parts for 4E-
BP1 staining. No positive sections or only one positively 
stained section was defined as having “low” expression of 
4E-BP1, and the presence of at least two positively stained 
sections was classified as “high” expression (Figure 3C). 
Table 1 indicates that 4E-BP1 expression in CRC patients 
does not correlate with age, gender, T factor (the size of the 
original tumor) or M factor (distant metastasis). However, 
we observed a significant statistical correlation with the 
N factor (lymph node invasion; p = 0.029) and 4E-BP1 
expression. It is noteworthy that 4E-BP1 expression was 
more prevalent in patients diagnosed at a late stage (stages 
III and IV; p = 0.027).
Survival analysis
The correlation between 4E-BP1 expression and 
clinical outcome was corroborated by a survival analysis. 
The patients enrolled in this study did not receive any 
chemotherapy before surgical resection. A Kaplan-Meier 
analysis showed that patients with negative results for 
4E-BP1 expression exhibited longer survival times 
(Figure 3A) and longer time to recurrence (Figure 3B; 
p = 0.028 and 0.003, respectively). Taken together, these 
results indicate that the expression levels of 4E-BP1 
directly correlate with CRC progression, patient survival, 
and recurrence. Therefore, 4E-BP1 could be a prognostic 
indicator and potential therapeutic target.
YXM110 inhibits 4E-BP1 expression under 
hypoxic conditions and suppresses  
cap-independent translation via 4E-BP1 deletion
Hypoxia is regarded as an obstacle to effective 
cancer therapy. It can cause a switch from cap-dependent 
to cap-independent translation [8], a process controlled 
mainly by 4E-BP1. As shown in Figure 1C, 4E-BP1 is 
upregulated in cancer cells under hypoxia, and YXM110 
has been shown to inhibit its expression [20]. Therefore, 
we assessed the ability of YXM110 to decrease 4E-BP1 
protein expression under hypoxic conditions. We observed 
that 4E-BP1 was significantly repressed by YXM110 under 
hypoxia, but this was not mediated by mTOR inhibition 
(Figure 4A). This implies that cap-independent translation 
is inhibited by YXM110. We confirmed that YXM110 
suppressed cap-independent translation when 4E-BP1 was 
overexpressed by using a bicistronic vector harboring cap-
dependent firefly luciferase and cap-independent Renilla 
luciferase genes (Figure 4B). Compared to paclitaxel, 
HCT116 cells under hypoxic conditions demonstrated 
increased sensitivity to YXM110 [20]. These results 
suggest that YXM110-induced 4E-BP1 depletion reduces 
the survival of cancer cells under oxygen-deprivation by 
making them more sensitive to anticancer agents.
YXM110 inhibits HIF-1α translation
The HIF-1 protein activates adaptive responses to 
hypoxic conditions [14]. During hypoxia, cap-dependent 
translation can switch to cap-independent (IRES-
dependent) translation of HIF-1α mRNA [6]. Therefore, 
mRNA and protein levels of HIF-1α were examined 
after YXM110 treatment under normoxia and hypoxia. 
We showed that HIF-1α mRNA expression is indeed 
increased during hypoxia (Figure 5). However, protein 
expression of HIF-1α was not detectable by western 
blot analysis (Figure 5B), suggesting that the translation 
process was blocked. Pretreatment with the proteasome 
inhibitor, MG132 could not reverse YXM110 mediated 
HIF-1α downregulation (Figure 5C). However, HIF-1β 
protein levels were also decreased after YXM110 
treatment (Supplementary Figure S2), including HIF-1β 
without IRES-dependent translation. There may be 
other mechanisms that facilitate YXM110 mediated 
HIF-1β downregulation. These results suggest that 
hypoxia-activated cap-independent translation is 
inhibited by YXM110.
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Figure 1: Compare 4E-BP1 expression in normal and colorectal cancer cells under normoxia and hypoxia. The detection 
of 4E-BP1 expression in normal colon cell line (CCD-18co) and colorectal cancer cells (SW480, SW620, Colo205, Caco-2, HCT116 and 
HT29) under A. normoxia and B. hypoxia. C. Also campare the difference of 4E-BP1 between normoxia and hypoxia on each one cell line.
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YXM110 inhibits HRE-luciferase activity and 
VEGF transcription and translation
HIF-1 is a known transcription factor for dozens of 
hypoxia induced target genes [13–16]. HIF-1 regulates 
transcription at the hypoxia-responsive element (HRE) 
domain of the promoter. Therefore, we measured the 
transcriptional activity of HIF-1 via the expression of 
the downstream target gene VEGF. HCT116 cells were 
transfected with a reporter plasmid containing five 
copies of HRE with the luciferase promoter gene. The 
transcriptional activity of HIF-1 in hypoxic cells was 
approximately 3,000 fold higher than in normoxic cells. 
However, YXM110 effectively inhibited the hypoxia-
induced transcriptional activity of HIF-1 (Figure 6A), and 
the transcription of hypoxia-increased VEGFA mRNA 
expression (Figure 6B). Furthermore, the levels of secreted 
VEGF decreased with YXM110 treatment (Figure 6C). 
Taken together, the results indicate that YXM110 inhibited 
HIF-1α translation and its transcriptional activity.
DISCUSSION
The aim of this study was to demonstrate the 
importance of 4E-BP1 expression in CRC. All colon 
cancer lines evaluated exhibited higher 4E-BP1 protein 
levels than normal cells under normoxia and hypoxia, 
and a tissue microarray confirmed this result in tumors. 
Moreover, 4E-BP1 expression positively correlated with 
poor prognosis. YXM110, a new phenanthroquinolizidine, 
notably suppressed 4E-BP1 expression under hypoxia, 
with concomitant inhibition of HIF-1α-regulated VEGFA 
transcription and translation. Therefore, we contend that 
4E-BP1 could be a valuable target for CRC treatment.
Translational regulation is crucial in cancer 
development and progression and can initiate tumor 
cell survival, angiogenesis, invasion, and metastasis. 
Translation of mRNAs is controlled by dual mechanisms at 
the level of initiation: cap-dependent and cap-independent 
(IRES-dependent) translation [6]. Substantial evidence 
has shown that global protein synthesis, which is mostly 
regulated by cap-dependent translation, promotes tumor 
cell growth and survival. In cap-dependent translation, 
the rate-limiting step of initiation is controlled by eIF4E, 
the 5′ cap-binding protein, 4E-BP1, and the eIF4E-
binding protein. Therefore, the roles of the interaction and 
expression of eIF4E and 4E-BP1 in cancer progression has 
been widely examined. mTOR hyperphosphorylated 4E-
BP1 is inactive and unable to bind to eIF4E in the steady 
state, indicating that eIF4E can initiate mRNA translation. 
Therefore, p-4E-BP1 is regarded as a proto-oncogene 
and even as a “funnel factor” in human cancers [21]. 
Many diverse oncogenic signals, such as Her2, Ras-Raf, 
and PI3K-Akt converge at 4E-BP1, affecting cancer cell 
Figure 2: Immnuohistochemical staining of 4E-BP1 in a tissue microarray. A. Representive 4E-BP1 staining of CRC 
specimens and corresponding non-cancerous tissues. B. The statisitc result of 4E-BP1 expression in CRC and paired normal specimens by 
Image J. ***P < 0.001.
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proliferation, invasion, and metastasis [22]. Studies have 
shown that in breast cancer, p-4E-BP1 is mainly expressed 
in poorly differentiated tumors, and correlates with tumor 
size, lymph node metastasis, and recurrence [23, 24]. The 
ratio of 4E-BP1 to eIF4E is an indicator of rapamycin 
sensitivity [25, 26] in cancer cells. Increasing evidence 
indicates that dephosphorylation of 4E-BP1 can serve as 
a clinical biomarker, and mimetic compounds of 4E-BP1 
have recently been developed [27].
However, cap-dependent mRNA translation is 
inhibited and cap-independent translation is enhanced in 
response to a variety of cell stressors, including growth 
arrest, nutrient deprivation, mitosis, hypoxia, and apoptosis 
[6, 11]. This suggests that cap-independent translation also 
plays an important role in cancer. Several studies have 
demonstrated that 4E-BP1 expression is elevated in human 
breast, prostate, head and neck, and some gastrointestinal 
cancers [28–30]. Furthermore, mTOR-independent 4E-BP1 
expression and phosphorylation have been reported as a 
mechanism of primary resistance to mTOR kinase inhibitors 
[31–33]. Reports have shown that colon cell origin is a 
strong predictor for mTOR inhibitor resistance [31, 32]. In 




(n = 98) (%) (n = 94) (%) p value
Age (years)
  ≦65 51 (52.0) 43 (45.7)
  >65 47 (48.0) 51 (54.2) 0.391
Gender
  Female 39 (39.8) 51 (54.3)
  Male 59 (60.2) 43 (45.7) 0.060
T factor
  1 5 (5.1) 2 (2.1)
  2 15 (15.3) 13 (13.8)
  3 55 (56.1) 55 (58.5)
  4 23 (23.5) 24 (25.5) 0.713
N factor
  0 50 (51.0) 33 (35.1)
  1+2 48(49.0) 61 (64.9) 0.029
M factor
  0 83 (84.7) 76 (80.9)
  1 15 (15.3) 18 (19.1) 0.567
Stage
  I 13 (13.3) 10 (10.6)
  II 33 (33.7) 20 (21.3)
  III 36 (36.7) 46 (48.9)
  IV 16 (16.3) 18 (19.1) 0.184
Stage
  Early 46 (46.9) 29 (30.9)
  Late 52 (53.1) 65 (69.1) 0.027
No positive or only one positively stained section was defined as “low” expression of 4E-BP1, and the presence of at least 
two positively stained sections was classified as “high” expression. (N = 192).
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Figure 3: Evaluation of the clinincal importance of 4E-BP1 expression in CRC patients. The correlation between 4E-BP1 
and A. survival time and B. recurrence time were analyzed by Kaplan-Meier analysis. C. The representative of immunohistochemical 
staining of 4E-BP1 on different stages of sections. Left lane shows the negative staining and right lane are the positive results.
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addition, 4E-BP1 overexpression is associated with poor 
prognosis and endocrine resistance in breast cancer [33].
As shown in Figure 1, compared to the normal colon 
cell line, all cancer cell lines tested had increased 4E-BP1 
levels under both normoxic and hypoxic conditions. The 
IHC staining of patient tumors provided strong evidence 
that 4E-BP1 is upregulated in cancerous tissues (Figure 2). 
Cell line analysis demonstrated that poor progression of 
CRC is associated with increased 4E-BP1 protein levels. 
These data are corroborated by the analysis of clinical 
pathology parameters. Patients with lymph node metastasis 
had statistically significant high 4E-BP1 expression, which 
correlated with late-stage CRC (Table 1). This was also 
associated with survival and recurrence time, as patients 
with low 4E-BP1 expression had better clinical outcomes 
(Figure 3).
We also determined the expression levels of eIF4E 
and p-4E-BP1 in colorectal cancer cell lines and normal 
cells. As shown in Supplementary Figure S1B and S1D, 
eIF4E and p-4E-BP1 were upregulated in most colorectal 
cancer cells under normoxia and hypoxia. However, it is 
noteworthy that the expression levels of eIF4E and p-4E-
BP1 were decreased in hypoxia compared to normoxia 
in most colorectal cells except for SW480 and SW620 
cells, which suggest a role for eIF4E and p-4E-BP1 in 
cap-dependent translation. Moreover, the analysis of 
clinical CRC tumor tissues indicates that there is a positive 
association between 4E-BP1 and eIF4E protein expression 
(Supplementary Table 1), suggesting that eIF4E may 
have a similar role as 4EBP in CRC tumorigenesis. 
Since the loss of 4E-BP1 or eIF4E overexpression can 
promote tumorigenesis, the ratio of 4E-BP1 to eIF4E in 
Figure 4: YXM110 suppresses cap-independent translation through 4E-BP1 deletion. A. HCT116 cells were treated with 
vehicle (0.1% DMSO) or YXM110 (0.1 or 0.3 μM) under normoxia or hypoxia conditions for 24 h. The cells were then harvested for 
detection of p-mTOR (Ser2448), eIF4E, 4E-BP1, p-4E-BP1 (Thr37/46), p-S6 (Ser240/244) and actin by western blot analysis. B. Bicistronic 
luciferase vector (pFR-Luc) contains a cap-dependent firefly (Fir) and cap-independent Renilla (Ren) luciferase. C. HCT116 cells were 
cotransfected bicistronic vector and wt 4E-BP1 for testing the effect of YXM110 on cap-dependent and cap-independent translation by 
using a dual Luciferase reporter system. *P < 0.05; ***P < 0.001; ###P < 0.001.
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colorectal cancer cells was also evaluated. Supplementary 
Figure S1C shows that the ratio of 4E-BP1 to eIF4E 
dramatically increased in cancer cells, especially under 
hypoxia.
Tumor hypoxia is considered as an obstacle 
to efficient cancer treatment with radiotherapy and 
chemotherapy because it acts as a barrier in the tumor 
region. Recent evidence has shown that tumor hypoxia 
is associated with more malignant phenotypes and 
poor prognosis. Therefore, developing selectively 
targeted therapy to hypoxic cells is an ongoing area 
of research [34]. In several reported studies, 4E-BP1 
has been demonstrated to be a positive regulator of 
cap-independent mRNA translation under hypoxic 
conditions. Tumor hypoxia induced 4E-BP1, decreases 
cap-dependent translation and activates cap-independent 
translation of mRNAs encoding HIF1α and VEGFA, 
which contributes to cell survival and angiogenesis [8]. 
YXM110 significantly depleted 4E-BP1 expression 
without mTOR inhibition, decreased 4E-BP1 mediated 
cap-independent translation HIF-1α translation and its 
transcriptional activity under hypoxia (Figures 4–6). 
These results suggest that YXM110 represses hypoxia-
activated cap-independent translation.
Based on the findings described in Table 1, we 
concluded that 4EBP1 expression is associated with 
N factor, which indicates that nearby (regional) lymph 
nodes are involved in CRC progression, as well as TNM 
stage. It has been reported that soluble VEGF-A was 
associated with lymphangiogenensis [35]. Moreover, 
the expression VEGF-A and VEGF-C was significantly 
elevated in CRCs, and tumors with lymph node metastases 
had significantly higher levels of VEGF-A compared with 
non-metastatic tumors [36, 37]. We therefore evaluated the 
expression levels of VEGF-A and VEGF-C after YXM110 
treatment and showed that YXM110 depleted VEGF-A 
and VEGF-C expression at the transcriptional level 
(Figure 6 and Supplementary Figure S3). However, it was 
found that hypoxia induces VEGF-C expression via a HIF-
1α-independent translation-mediated mechanism [38]. 
We speculated that VEGF-C translational downregulation 
might be due to YXM110 mediated cap-independent 
inhibition rather than a 4E-BP1-HIF-1αpathway.
Akt/mTOR signaling is known to regulate protein 
synthesis. YXM110 was proved to have an ability to inhibit 
protein synthesis even that YXM110 induced mTOR 
signaling activation (Figure 4A) [20]. It was also shown 
that extracellular signals activate mTOR, which in turns 
Figure 5: YXM110 inhibits HIF-1α translation. A. HIF-1α mRNA was analyzed with quantitative real-time RT-PCR after 6 h 
treatment of YXM110 (0.1 or 0.3 μM) under normoxia or hypoxia conditions. B. HCT116 cells were treated with vehicle (0.1% DMSO) or 
YXM110 (0.1 or 0.3 μM) under normoxia or hypoxia conditions for 24 h or C. pretreated with vehicle or 10 μM MG132 and then incubated 
with vehicle or YXM110 (0.1 or 0.3 μM) for 24 h under hypoxia. The cells were then harvested for detection of HIF-1α and actin by western 
blot analysis. *P < 0.05; ##P < 0.01.
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triggers HIF-1α induction though transcriptional regulation 
[39]. Although HIF-1α mRNA was induced after treatment 
with YXM110, HIF-1α protein was profoundly suppressed 
by YXM110 in a translational manner (Figure 5). Hypoxia 
can cause cell cycle arrest and simultaneously suppresses 
conversion from proliferative arrest to cellular senescence 
[40-41]. Nonetheless, inhibition of 4E-BP1 can sensitize 
cells, which is hypoxia tolerance and radioresistance, to 
chemotherapy and irradiation [42]. We recently reported 
that compared to anticancer drugs, YXM110 can reduce 
the survival of cancer cells during hypoxia [20]. These 
combined observations strongly suggest that YXM110, an 
inhibitor of 4E-BP1, may be an effective agent for treating 
drug-resistant CRC.
In conclusion, to the best of our knowledge, this 
study is the first to demonstrate the significance of 4E-
BP1 in CRC through clinical data. Although 4E-BP1 
expression is paradoxically elevated in some tumors and 
can act as a tumor suppressor or proto-oncogene, we 
emphasize that, in this study, the expression of 4E-BP1 is 
associated with poor prognosis in CRC. Here we provide 
a novel mechanism of action for the cryptopleurine 
derivative, YXM110. We show that it significantly 
depletes 4E-BP1 expression and subsequently induces 
the suppression of cap-independent translation with the 
inhibition of HIF-1α-regulated VEGFA transcription 
under hypoxia, which facilitates drug resistance. 
Therefore, from a therapeutic perspective, 4E-BP1 could 
Figure 6: YXM110 inhibits HRE-Luciferases activity and VEGF transcription and translation. A. HCT116 cells 
transiently transfected with 5-HRE-Luciferase reporter were treated with YXM110 under normoxia or hypoxia conditions for 24 h. Data 
have shown represented luciferase activity relative to the control. B. VEGFA mRNA was analyzed with quantitative real-time RT-PCR after 
6 h treatment of YXM110 (0.1 or 0.3 μM) under normoxia or hypoxia conditions. C. VEGF levels in culture medium were determined using 
Human VEGF Quantikine ELISA Kit. ***P < 0.001; ###P < 0.001.
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be a promising prognostic marker and an excellent drug 
target for treatment of CRC. Accordingly, YXM110 is 
a potential lead therapeutic compound, particularly for 
treatment of drug-resistant CRC.
MATERIALS AND METHODS
Study subjects
Primary colorectal cancer patients were admitted 
to Taipei Medical University Hospital, China Medical 
University Hospital and Chung Shan Medical University 
Hospital. All of them wrote informed consent approved by 
the Institutional Review Board (IRB number: 201402018 
and 201312018). The enrolled patients did not receive 
any chemotherapy or radiation therapy prior to surgery. 
The TNM stages of all colorectal cancer patients were 
determined according to the American Joint Committee 
on Cancer/International Union Against Cancer TNM 
staging system.
Immunohistochemical staining for 4E-BP1 
protein expression
Non-cancerous and colorectal cancer tissues were 
sectioned from patients and formalin-fixed and paraffin-
embedded. These sections were deparaffinized with 
xylen, rehydrated in different concentration of alcohol 
and immersed in 3% H202 for removing endogenous 
peroxidase. Sections were heated in a microwave in citrate 
buffer (pH 6.0) for antigen retrieval. Washing with PBS, 
the sections were blocked with 3% BSA/PBS for 30 min 
and incubated with anti-4E-BP1 antibody (Cell Signaling) 
at 4°C overnight. The streptavidin peroxidase method was 
performed (Dako, LSAB kit) to develop the signal.
Cell culture and hypoxia
Human colorectal cancer cell line HCT116, HT-29 
and Colo205 were purchased from American Type Culture 
Collection (ATCC; Manassas, VA, USA). SW480, SW620, 
Caco-2 and CCD-18co were kindly gift from Min-Chuan 
Huang (Graduate institute of Anatomy and Cell Biology, 
College of Medicine, National Taiwan University) and 
Kuen-Haur Lee (Program for Cancer Biology and Drug 
Discovery, College of Medical Science and Technology, 
Taipei Medical University). HCT116, HT-29 and Colo205 
were cultured in RPMI-1640 medium (Gibco, Invitrogen, 
Carlsbad, CA, USA); SW480, SW620 and Caco-2 were 
maintained in DMEM medium (Gibco, Invitrogen, 
Carlsbad, CA, USA); CCD-18co was in MEM medium 
(Gibco, Invitrogen, Carlsbad, CA, USA). All of them were 
supplemented with 10% heat-inactivated FBS, penicillin 
100 U/ml, streptomycin 100 μg/ml, and amphotericin B 
2.5 μg/ml. Cells were maintained at 37°C in a humidified 
incubator with 5% CO2/95% air. Hypoxia incubations 
were performed in hypoxia chamber, which was flushed 
with 1% O2, 5% CO2, and 94% N2 at 37°C (BioSpherix 
Proox 110), and incubated for the indicated time.
Western blot analysis
For total lysate, cells were lysed with the 120 
μL ice-cold lysis buffer [10 mmol/L Tris-HCl (pH 
7.4), 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L 
phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, 10 
μg/mL leupeptin, 1 mM sodium orthovandate, 1 mM NaF, 
and 1% Triton X-100]. Cell lysates were centrifuged at 13, 
000 rpm for 30 min. For Western blot analysis, the amount 
of protein (40–60 μg) was separated by electrophoresis 
in 10%-15% polyacrylamide gels and transferred to 
polyvinylidene difluoride (PVDF) membranes. After 
1 h incubation at room temperature in PBS/5% nonfat 
milk, the membrane was washed with PBS/0.1% Tween 
20 and incubated with the indicated antibodies at 4°C 
overnight. After washing with PBS/0.1% Tween 20, 
the corresponding secondary antibodies were applied 
to the membranes for 1 h at room temperature. The 
membranes were then washed with PBS/0.1% Tween 20 
and the detection of signal was done with an enhanced 
chemiluminescence detection kit.
Quantitative RT-PCR
Total RNA was extracted with TRIzol reagent by 
the manufacturer’s protocol (Invitrogen, USA). 5 μg 
mRNA was incubated with random primer at 65°C for 
5 min, then mixed with M-MLV RT at 37°C for 1 h to 
obtain cDNA. The SYBR Green PCR reaction (SYBR® 
Green PCR Master Mix; Roche, Switzerland) was used to 
evaluate the amplification of HIF-1α and VEGFA genes. 
Primer sequences used for amplification are as follows: 
HIF-1α, 5′-ATC CAT GTG ACC ATG AGG AAA TG-
3′ and 3′-TCG GCT AGT TAG GGT ACA CTT C-5′; 
HIF-1β, 5′-TTTATCCCTAGAGATGGGTACAGG-3′ 
and 5′-CCACAGGCTGGACAGAAACC-3; VEGFA, 
5′-AAC CAT GAG TTT ATC GCC ACC-3′ and 5′-
AGC GTT ACA TTG CCT GCA TTT-3′; VEGF-C, 
5′-GCCAACCTCAACTCAAGGAC-3′ and 5′-CCCACA 
TCTGTAGACGGACA-3′. Fluorescent signal was 
detected and recorded by StepOne Real-Time PCR System 
(Applied Biosystems, USA), and each amplification 
reaction was checked for the absence of nonspecific PCR 
products by melting curve. Relative fold changes in gene 
expression are calculated as 2-∆∆Ct.
Transient transfection
For luciferase assay, cells were seeded in 24-
well plates (15,000 cells/well) overnight, and then 
transfected with 5-HRE-Luciferase reporter plasmid with 
Lipofectamine 2000 Transfection Reagent (Invitrogen) 
according to the manufacturer’s protocol. HCT116 cells 
Oncotarget24103www.impactjournals.com/oncotarget
were treated with vehicle (0.1% DMSO) or YXM110 
(0.1 or 0.3 μM) under normoxia or hypoxia conditions 
for 24 h. The promoter activity was determined by using 
Luciferase Assay System (#E1500) from Promega. For 
cap-dependent and cap-independent translation assay, 
cells overexpressing wild-type 4E-BP1 were transfected 
with pFR-LUCs plasmid, which is a kind gift from Tarn, 
Woan-Yuh (Institutive of Biomedical Sciences, Academia 
Sinica, Taiwan), expressing bicistronic mRNA reporter 
containing a cap-dependent firefly luciferase and Renilla 
luciferase. The dual luciferase activity was determined by 
using Dual-Luciferase® Reporter Assay (Promega).
VEGF ELISA
HCT116 cells were seeded in 24-well (15,000 cells/
well) overnight, and then treated with vehicle or YXM110 
under normoxia or hypoxia conditions for 24 h. Culture 
medium were collected to measure the amount of VEGF by 
Human VEGF Quantikine ELISA Kit (R&D, Minneapolis, 
USA) according to the manufacturer’s instructions.
Statistical analysis
Logistic regression analysis was used to assess the 
association of 4E-BP1 and age, gender, tumor progression. 
Survival and recurrence time were estimated by Kaplan-
Meier method. And data were expressed as mean ± SEM of 
the indicated number for separate experiments. Statistical 
analysis of data was performed with one-way ANOVA 
followed by the Student’s t test, and p < 0.05 were considered 
significant (*P < 0.05, **P < 0.01, ***P < 0.001).
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